American Healthcare REIT, Inc. (AHR) Stock Price & How to Invest

American Healthcare REIT owns and operates a diversified clinical healthcare property portfolio across the United States, the United Kingdom and the Isle of Man. It reports in four segments: integrated senior health campuses (ISHC, essentially the Trilogy Health Services platform of 130-plus combined senior living and skilled nursing campuses in Ohio, Kentucky, Indiana, Michigan and Wisconsin), senior housing operating properties (SHOP), outpatient medical buildings, and triple-net leased facilities. ISHC and SHOP together produce the large majority of net operating income, which is the single most important fact about the company: those are RIDEA-style structures where AHR receives the property's operating profit after staffing, food and insurance costs, not a fixed rent check. AHR became sole owner of Trilogy REIT Holdings in September 2024 after buying out the remaining 24% minority interest, which concentrated the earnings power (and the operating risk) inside the company.

The investment picture is a demographic story colliding with a valuation question. Senior housing is absorbing the leading edge of the 80-plus population wave at the same time that construction starts sit near multi-decade lows, so occupancy and rate growth have both run hot. In the second quarter of 2026 (reported August 6) AHR posted its tenth consecutive quarter of double-digit same-store NOI growth: ~13.2% for the total portfolio, ~20.5% in SHOP and ~16.1% in ISHC, with normalized FFO of $0.54 per diluted share. Management raised full-year 2026 NFFO guidance to $2.15 to $2.19 per share (more than 5% above the prior midpoint) and same-store NOI growth to 11% to 13%. AHR has also become far more acquisitive: it closed more than $1.4 billion of new investments in 2026 through early August, including ten SHOP communities for about $1.0 billion after quarter end, and still reports a pipeline of over $800 million. It funded much of that with equity (a May follow-on of about $811 million in forward sales plus at-the-market issuance), which pushed leverage down to about 2.5x net debt to annualized adjusted EBITDA with roughly $2.6 billion of liquidity. The offset is price: with the stock near $53 and a market cap around $11.5 billion, AHR trades at roughly 24 times the midpoint of 2026 NFFO guidance and yields under 2%, well below where healthcare REITs have historically been bought for income. That combination means the shares are priced for the operating momentum to persist.

The same RIDEA structure that creates the upside removes the cushion on the way down: if occupancy stalls or wage and insurance inflation reaccelerate, NOI falls straight to the bottom line with no lease floor underneath it. Skilled nursing and the ISHC segment carry meaningful Medicare and Medicaid reimbursement exposure, so federal or state rate decisions and any tightening of Medicaid funding are genuine earnings risks that AHR does not control. Valuation is its own risk factor: at roughly 24 times 2026 NFFO guidance and a GAAP P/E near 79, the shares leave little room for a guidance miss, and the sub-2% dividend yield offers little support if the growth narrative cools; the stock is down about 8% over the past three months even after the guidance raise. Heavy equity issuance in 2026 (follow-on and ATM forward sales well above $1 billion) means growth has to outrun dilution, and roughly $1 billion of senior housing bought in a single summer raises integration and pricing risk. Concentration matters too, with the Trilogy platform in five Midwestern states responsible for a large share of portfolio NOI. Finally, as a heavily acquisitive REIT, AHR depends on continued access to equity and debt on favorable terms, and a change in rates or sentiment toward senior housing would make the external growth engine much more expensive to run.

16 analysts publish price targets on AHR, averaging $63.69 against a $53.67 price as of November 2026, or +18.7%. The published targets run from $55.00 to $74.00, a narrow spread, and the ratings split 16 buy, 0 hold, 0 sell. Over the last six months there have been 8 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full AHR forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on American Healthcare REIT, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The 80-plus demographic wave meeting a supply drought. The population aged 80 and over is entering its fastest growth stretch in modern history, while senior housing construction starts have been running near multi-decade lows since the pandemic and higher rates made new development uneconomic. The most optimistic published target, $74.00, assumes this works close to its best case.

The case against. The same RIDEA structure that creates the upside removes the cushion on the way down: if occupancy stalls or wage and insurance inflation reaccelerate, NOI falls straight to the bottom line with no lease floor underneath it. The most pessimistic target, $55.00, is roughly what AHR is worth if this bites instead.

Read the full bull and bear case on AHR, including what would have to change to break either one. Walnut is not an investment adviser.

No. American Healthcare REIT, Inc. (AHR) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see American Healthcare REIT, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$2.5B, up ~24.7% year over year in Q2 2026
• 2026 normalized FFO guidance: ~$2.15 to $2.19 per diluted share, raised in August (Q2 2026 NFFO was ~$0.54)
• Same-store NOI growth: ~13.2% in Q2 2026; full-year 2026 guidance ~11.0% to 13.0%
• Net income (TTM): ~$121M (~$0.67 GAAP EPS, trailing P/E ~79x)
• Dividend: ~$1.00 annualized ($0.25 quarterly), ~1.9% yield
• Net debt to annualized adjusted EBITDA: ~2.5x at June 30, 2026, with ~$1.4B of consolidated debt and ~$2.6B of liquidity
• Market cap / implied multiple: ~$11.5B at roughly $53 per share, about ~24x the midpoint of 2026 NFFO guidance

For a REIT, FFO and AFFO matter more than reported EPS because large non-cash depreciation charges push GAAP net income far below actual cash generation, which is why AHR's headline P/E near 79 looks nothing like its mid-20s multiple of normalized FFO. The multiple has eased a little since August because guidance rose while the share price slipped, but it is still a premium to the healthcare REIT group, and the market is effectively underwriting several more years of the double-digit same-store NOI growth AHR has delivered for ten straight quarters. The unusual feature versus most REITs is the yield: under 2% means this is being priced as a growth equity rather than an income holding. Third-quarter results arrive November 5, 2026.

If you want AHR exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to AHR: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get AHR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (SCHA), which spreads the position across many companies. Or build it into a focused thematic portfolio, so AHR sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where AHR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

AHR is a growth-phase healthcare REIT whose earnings track senior housing occupancy and labor costs. It raised 2026 guidance again in August after a tenth straight quarter of double-digit same-store NOI growth and more than $1.4 billion of new investments, and the market is already paying a premium multiple (about 24x 2026 NFFO guidance) for that growth to continue. Third-quarter results are due November 5, 2026.

Whether AHR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AHR a buy or a sell?, and where the stock could go from here in the AHR stock forecast.

For income investors, whether AHR pays a dividend and how the payout looks is covered in does AHR pay a dividend? And to weigh AHR against a peer, read the full side-by-side comparisons: AHR vs WELL and AHR vs VTR.